酒精消费和心力衰竭:一个剂量反应元分析
Bethany Wong1,2, Cristin Ryan3, Adeniyi Fagbamigbe4,5
1School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
The Cochrane database of systematic reviews
|August 9, 2024
概括
本综述探讨了酒精消费如何影响高风险人群的心力衰竭的进展. 它评估酒精的酒精含量.
科学领域:
- 心脏病学和心血管健康
- 公共卫生和预防医学
- 与酒精有关的研究
背景情况:
- 心力衰竭是一个重要的全球健康问题.
- 识别可修改的风险因素,如酒精消费,对于预防至关重要.
- 心力衰竭的早期阶段 (A和B阶段) 提供了干预的机会.
研究的目的:
- 评估酒精消费对症状性心力衰竭 (C期) 的进展的影响.
- 评估酒精对早期心力衰竭中左心室功能障碍的影响.
- 研究酒精在不同类型心力衰竭 (HFrEF,HFmrEF,HFpEF) 的发展中的作用.
主要方法:
- 这项研究概述了科克伦审查的协议.
- 将采用系统审查方法来综合现有证据.
- 该审查将重点关注心力衰竭风险或早期心力衰竭的个体.
主要成果:
- 本节不适用,因为输出是一个协议.
- 结果将在系统审查完成后确定.
- 该审查旨在量化酒精摄入量与心力衰竭发展之间的关联.
结论:
- 了解酒精对心力衰竭进展的影响对于临床指南至关重要.
- 可以制定基于证据的建议,以减轻与酒精有关的心血管风险.
- 这一审查将明确酒精消费在心力衰竭发展中的作用.
更多相关视频
05:40The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
Published on: April 28, 2022
3.0K
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
7.9K
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
